Galmed Pharmaceuticals (GLMD) Operating Income (2013 - 2020)

Galmed Pharmaceuticals' Operating Income history runs 8 years deep, the most recent figure standing at $6.5 million for Q1 2020.

• In Q1 2020, Operating Income rose 59.95% year-over-year to $6.5 million; the TTM figure through Mar 2020 stood at $16.3 million (up 19.44% YoY), while the FY2024 annual figure was $1.7 million, up 8.74% from the prior year.
• Operating Income was $6.5 million for Q1 2020 at Galmed Pharmaceuticals, up from $4.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $6.5 million in Q1 2020 to a low of $2.6 million in Q1 2018.
• Historically, Operating Income has averaged $4.1 million across 5 years, with a median of $4.0 million in 2019.
• The sharpest annual moves came in 2016 and 2018: Operating Income jumped 66.9% in 2016, then dropped 21.6% in 2018.
• A 5-year view of Operating Income shows it stood at $3.8 million in 2016, then fell by 14.22% to $3.3 million in 2017, then slipped by 21.6% to $2.6 million in 2018, then jumped by 57.87% to $4.0 million in 2019, then jumped by 59.95% to $6.5 million in 2020.
• The last three Operating Income figures came in at $6.5 million (Q1 2020), $4.0 million (Q1 2019), and $2.6 million (Q1 2018), per Business Quant data.